Michelson Diagnostics develops, manufactures and markets VivoSight, a point-of-care, scanning device that provides clinicians with a unique, non-invasive tool for diagnosing a variety of skin pathologies.

VivoSight uses light to provide continuous and accurate images of the sub-surface of the skin that can be easily interpreted by a clinician to assist in diagnosis and treatment guidance. VivoSight has CE Mark in Europe and TGA regulatory-clearance in Australia for use in the diagnosis of non-melanoma skin cancers (NMSC). Given the unprecedented image resolution and image quality, VivoSight has many potential clinical applications beyond the initial focus in dermatology. VivoSight is currently sold in Germany where the scans are reimbursed for patients with private healthcare insurance. Further clinical studies are presently being conducted at leading centres in the United States, where VivoSight currently has 510(k) clearance. Michelson Diagnostics is based in Maidstone, Kent, UK.